甲磺酸阿帕替尼治疗晚期胃癌的疗效及安全性分析  

Clinical Efficacy and Safety of Apatinib Mesylatefor Patients with Advanced Gastric Cancer

作　　者：郎丰平[1] 赵毓毅[1] 范鹏[1] 

机构地区：[1]山东省淄博万杰肿瘤医院,255213

出　　处：《实用癌症杂志》2017年第6期996-998,共3页The Practical Journal of Cancer

摘　　要：目的探讨甲磺酸阿帕替尼治疗晚期胃癌的临床疗效及安全性。方法回顾性分析接受甲磺酸阿帕替尼治疗的晚期胃癌患者28例,既往均接受过二线及二线以上治疗。14例患者作为对照组接受甲磺酸阿帕替尼模拟片,14例患者作为观察组接受甲磺酸阿帕替尼片,剂量均为850 mg,1次/天,早餐后服用。采用RECIST、NCI以及CTC标准对比分析2组患者治疗疗效以及药物不良反应。结果观察组患者PR、SD、PD、RR以及DCR显著优于对照组,差异具统计学意义(P<0.05);但2组患者OS和PFS相比较,差异不具统计学意义(P>0.05)。观察组中AFP阳性胃癌患者OS和PFS显著高于AFP阴性胃癌患者,差异具统计学意义(P<0.05)。甲磺酸阿帕替尼主要不良反应表现为骨髓抑制等血液毒性和手足综合征等非血液毒性,其中高血压发生率为64.3%、骨髓抑制发生率为78.6%,不良反应发生多为Ⅰ~Ⅱ级,无Ⅳ级不良反应发生。结论甲磺酸阿帕替尼治疗晚期胃癌,疗效确切,不良反应患者可耐受,可推广使用。Objective To analyze the clinical efficacy and safety of apatinib mesylate in the treatment of patients with advanced gastric cancer. Methods A retrospective analysis of 28 patients with advanced gastric cancer received apatinib mesylate treatment were conducted,all patients had previously received second-line or more than second-line treatment,14 patients in the control group received the apatinib mesylate simulation tablets,14 patients in the observation group received apatinib mesylate tablets,doses were 850 mg,1 times/d,patients took it after breakfast. Using RECIST,NCI and CTC standard to compare and analyze the curative effect and adverse drug reaction between the 2 groups. Results The incidence of PR,SD,PD,RR and DCR in the observation group were significantly higher than those of the control group,the difference was statistically significant（ P〈0. 05）. The differences between the 2 groups in PFS and OS were not statistically significant（ P〈0. 05）; the PFS and OS of AFP positive gastric cancer patients in the observation group were significantly higher than the AFP negative patients with gastric cancer,the difference was statistically significant（ P〈0. 05）. The main adverse reactions of apatinib mesylate were blood toxicity such as bone marrow suppression and non hematologic toxicity such as hand foot syndrome and so on,the incidence of hypertension was64. 3%,and the incidence of bone marrow suppression was 78. 6%,the incidence of adverse reactions was grade Ⅰ to Ⅱ,and the incidence of adverse reaction was 0. 0%. Conclusion Apatinib mesylate in the treatment of advanced gastric cancer survival benefit is exact,its adverse reactions are tolerable,and it can be popularized.

关 键 词：甲磺酸阿帕替尼 晚期胃癌 临床疗效 不良反应 

分 类 号：R735.2[医药卫生—肿瘤]